Apogee Therapeutics (APGE) Stock Forecast & Price Target

Compare

348 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

APGE Analyst Ratings

Strong Buy

13 Buy

2 Hold

0 Sell

Based on 15 analysts giving stock ratings to

Apogee

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

APGE Stock 12 Month Forecast

Average Price Target

$105.67

▲(61.30% Upside)

Based on 15 Wall Street analysts offering 12 month price targets for Apogee Therapeutics in the last 3 months. The average price target is $105.67 with a high forecast of $137.00 and a low forecast of $83.00. The average price target represents a 61.30% change from the last price of $65.51.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"30":"$30","57":"$57","84":"$84","111":"$111","138":"$138"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":137,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$137.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":105.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$105.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":83,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$83.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[30,57,84,111,138],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,75.48,80.21230769230769,84.94461538461539,89.67692307692307,94.40923076923077,99.14153846153846,103.87384615384616,108.60615384615384,113.33846153846153,118.07076923076923,122.80307692307693,127.53538461538461,132.2676923076923,{"y":137,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,75.48,77.80230769230769,80.12461538461538,82.44692307692308,84.76923076923077,87.09153846153846,89.41384615384615,91.73615384615385,94.05846153846154,96.38076923076923,98.70307692307692,101.02538461538461,103.34769230769231,{"y":105.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,75.48,76.05846153846154,76.63692307692308,77.21538461538462,77.79384615384616,78.3723076923077,78.95076923076924,79.52923076923076,80.1076923076923,80.68615384615384,81.26461538461538,81.84307692307692,82.42153846153846,{"y":83,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":45.3,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.36,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.44,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.61,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.2,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.33,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.26,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.75,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.86,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.38,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.59,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.96,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.48,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$137.00

Average Price Target$105.67

Lowest Price Target$83.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Geoff Meacham

Citi

$95

Buy

45.02%

Upside

Reiterated

01/30/26

Analysts Are Bullish on These Healthcare Stocks: Concentra Group Holdings Parent, Inc. (CON), Apogee Therapeutics (APGE)

Joseph Catanzaro

Mizuho Securities

Buy

―

Reiterated

01/29/26

Analysts Offer Insights on Healthcare Companies: Fractyl Health, Inc. (NASDAQ: GUTS), GE Healthcare Technologies Inc (NASDAQ: GEHC) and Apogee Therapeutics (NASDAQ: APGE)

Tazeen Ahmad

Bank of America Securities

$84

Buy

28.22%

Upside

Reiterated

01/27/26

Analysts Offer Insights on Healthcare Companies: Apogee Therapeutics (NASDAQ: APGE), Alphatec Holdings (NASDAQ: ATEC) and Hyperfine (NASDAQ: HYPR)

Julian Harrison

BTIG

$137

Buy

109.13%

Upside

Reiterated

01/26/26

Analysts Offer Insights on Healthcare Companies: Maze Therapeutics, Inc. (NASDAQ: MAZE), Pelthos Therapeutics (NYSE MKT: PTHS) and Apogee Therapeutics (NASDAQ: APGE)

Seamus Fernandez

Guggenheim

$130

Buy

98.44%

Upside

Reiterated

01/23/26

Guggenheim Reaffirms Their Buy Rating on Apogee Therapeutics (APGE)

Michael Yee

UBS

$100

Buy

52.65%

Upside

Reiterated

01/23/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Apogee Therapeutics (NASDAQ: APGE) and Neurocrine (NASDAQ: NBIX)

Brian Abrahams

RBC Capital

$70→$83

Hold

26.70%

Upside

Downgraded

01/22/26

Apogee Therapeutics downgraded to Sector Perform from Outperform at RBC CapitalApogee Therapeutics downgraded to Sector Perform from Outperform at RBC Capital

Andy Chen

Wolfe Research

Hold

―

Initiated

01/07/26

Apogee Therapeutics initiated with a Peer Perform at Wolfe ResearchApogee Therapeutics initiated with a Peer Perform at Wolfe Research

Adam Vogel

Craig-Hallum

$109→$116

Buy

77.07%

Upside

Reiterated

01/07/26

Apogee Therapeutics (APGE) Gets a Buy from Craig-Hallum

Alex Thompson CFA

Stifel Nicolaus

$95→$133

Buy

103.02%

Upside

Reiterated

01/06/26

Apogee Therapeutics: Differentiated IL-13 Strategy, Durable Efficacy, and 2026 Catalysts Underpin Reaffirmed Buy Rating

Edward Nash

Canaccord Genuity

$89

Buy

35.86%

Upside

Reiterated

01/06/26

Canaccord Genuity Keeps Their Buy Rating on Apogee Therapeutics (APGE)

Sudan Loganathan

Stephens

$95

Buy

45.02%

Upside

Initiated

12/17/25

Apogee Therapeutics initiated with an Overweight at StephensApogee Therapeutics initiated with an Overweight at Stephens

David Hoang

Deutsche Bank

$103

Buy

57.23%

Upside

Initiated

12/10/25

Apogee Therapeutics initiated with a Buy at Deutsche BankApogee Therapeutics initiated with a Buy at Deutsche Bank

Unknown Analyst

Roth MKM

Not Ranked

Roth MKM

$103

Buy

57.23%

Upside

Initiated

12/10/25

Apogee Therapeutics (APGE) Receives a New Rating from Roth MKM

Tyler Van Buren

TD Cowen

Buy

―

Reiterated

12/03/25

Analysts Are Bullish on These Healthcare Stocks: Apogee Therapeutics (APGE), Alvotech (ALVO)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Geoff Meacham

Citi

$95

Buy

45.02%

Upside

Reiterated

01/30/26

Analysts Are Bullish on These Healthcare Stocks: Concentra Group Holdings Parent, Inc. (CON), Apogee Therapeutics (APGE)

Joseph Catanzaro

Mizuho Securities

Buy

―

Reiterated

01/29/26

Analysts Offer Insights on Healthcare Companies: Fractyl Health, Inc. (NASDAQ: GUTS), GE Healthcare Technologies Inc (NASDAQ: GEHC) and Apogee Therapeutics (NASDAQ: APGE)

Tazeen Ahmad

Bank of America Securities

$84

Buy

28.22%

Upside

Reiterated

01/27/26

Analysts Offer Insights on Healthcare Companies: Apogee Therapeutics (NASDAQ: APGE), Alphatec Holdings (NASDAQ: ATEC) and Hyperfine (NASDAQ: HYPR)

Julian Harrison

BTIG

$137

Buy

109.13%

Upside

Reiterated

01/26/26

Analysts Offer Insights on Healthcare Companies: Maze Therapeutics, Inc. (NASDAQ: MAZE), Pelthos Therapeutics (NYSE MKT: PTHS) and Apogee Therapeutics (NASDAQ: APGE)

Seamus Fernandez

Guggenheim

$130

Buy

98.44%

Upside

Reiterated

01/23/26

Guggenheim Reaffirms Their Buy Rating on Apogee Therapeutics (APGE)

Michael Yee

UBS

$100

Buy

52.65%

Upside

Reiterated

01/23/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Apogee Therapeutics (NASDAQ: APGE) and Neurocrine (NASDAQ: NBIX)

Brian Abrahams

RBC Capital

$70→$83

Hold

26.70%

Upside

Downgraded

01/22/26

Apogee Therapeutics downgraded to Sector Perform from Outperform at RBC CapitalApogee Therapeutics downgraded to Sector Perform from Outperform at RBC Capital

Andy Chen

Wolfe Research

Hold

―

Initiated

01/07/26

Apogee Therapeutics initiated with a Peer Perform at Wolfe ResearchApogee Therapeutics initiated with a Peer Perform at Wolfe Research

Adam Vogel

Craig-Hallum

$109→$116

Buy

77.07%

Upside

Reiterated

01/07/26

Apogee Therapeutics (APGE) Gets a Buy from Craig-Hallum

Alex Thompson CFA

Stifel Nicolaus

$95→$133

Buy

103.02%

Upside

Reiterated

01/06/26

Apogee Therapeutics: Differentiated IL-13 Strategy, Durable Efficacy, and 2026 Catalysts Underpin Reaffirmed Buy Rating

Edward Nash

Canaccord Genuity

$89

Buy

35.86%

Upside

Reiterated

01/06/26

Canaccord Genuity Keeps Their Buy Rating on Apogee Therapeutics (APGE)

Sudan Loganathan

Stephens

$95

Buy

45.02%

Upside

Initiated

12/17/25

Apogee Therapeutics initiated with an Overweight at StephensApogee Therapeutics initiated with an Overweight at Stephens

David Hoang

Deutsche Bank

$103

Buy

57.23%

Upside

Initiated

12/10/25

Apogee Therapeutics initiated with a Buy at Deutsche BankApogee Therapeutics initiated with a Buy at Deutsche Bank

Unknown Analyst

Roth MKM

Not Ranked

Roth MKM

$103

Buy

57.23%

Upside

Initiated

12/10/25

Apogee Therapeutics (APGE) Receives a New Rating from Roth MKM

Tyler Van Buren

TD Cowen

Buy

―

Reiterated

12/03/25

Analysts Are Bullish on These Healthcare Stocks: Apogee Therapeutics (APGE), Alvotech (ALVO)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Apogee Therapeutics

3 Months

xxx

Success Rate

6/8 ratings generated profit

Average Return

+21.89%

reiterated a xxx

rating 2 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +21.89% per trade.

1 Year

Geoff MeachamCiti

Success Rate

8/8 ratings generated profit

Average Return

+72.08%

reiterated a buy rating 2 days ago

Copying Geoff Meacham's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +72.08% per trade.

2 Years

xxx

Success Rate

6/6 ratings generated profit

Average Return

+94.33%

reiterated a xxx

rating 9 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +94.33% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

APGE Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, APGE has received 32 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. APGE average Analyst price target in the past 3 months is 105.67.

Each month's total comprises the sum of three months' worth of ratings.

APGE Financial Forecast

APGE Earnings Forecast

Next quarter’s earnings estimate for APGE is -$1.05 with a range of -$1.23 to -$0.87. The previous quarter’s EPS was -$1.11. APGE beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.25% of the time in the same period. In the last calendar year APGE has Performed in-line its overall industry.

No data currently available

APGE Sales Forecast

Next quarter’s sales forecast for APGE is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. APGE beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.18% of the time in the same period. In the last calendar year APGE has Performed in-line its overall industry.

APGE Stock Forecast FAQ

What is APGE’s average 12-month price target, according to analysts?

Based on analyst ratings, Apogee Therapeutics’s 12-month average price target is 105.67.

What is APGE’s upside potential, based on the analysts’ average price target?

Apogee Therapeutics has 61.30% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is APGE a Buy, Sell or Hold?

Apogee Therapeutics has a consensus rating of Strong Buy which is based on 13 buy ratings, 2 hold ratings and 0 sell ratings.

What is Apogee Therapeutics’s price target?

The average price target for Apogee Therapeutics is 105.67. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $137.00 ,the lowest forecast is $83.00. The average price target represents 61.30% Increase from the current price of $65.51.

What do analysts say about Apogee Therapeutics?

Apogee Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of APGE?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Apogee Therapeutics (APGE) Stock Forecast & Price Target

APGE Analyst Ratings

APGE Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Apogee Therapeutics

APGE Analyst Recommendation Trends

APGE Financial Forecast

APGE Earnings Forecast

APGE Sales Forecast

APGE Stock Forecast FAQ

Detailed List of Analyst Forecasts